Imagion highlights MRI contrast agent study at SABCS

Imagion Biosystems presented positive results from a phase I trial evaluating its experimental MRI contrast agent at the recent San Antonio Breast Cancer Symposium.The company’s MagSense HER2 Imaging Agent (MSH2IA) was safe and well-tolerated in 13 patients diagnosed with HER2+ breast cancer, according to the findings. MSH2IA was designed as an adjunct to MRI for the assessment of axillary lymph node metastasis in patients diagnosed with HER2+ primary breast cancer.The trial met its endpoints of safety and tolerability, and showed that blinded radiologists may be able to distinguish suspicious lymph nodes that are infiltrated with metastatic HER2+ cancer from those involved in a healthy immune response or otherwise normally reactive, the company said.
Source: AuntMinnie.com Headlines - Category: Radiology Authors: Tags: Industry News Source Type: news